Blueprint Medicines Corporation is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The following report cites that, “To emulate the systemic nature of the disease, the company developed an aggressive systemic mouse model of SM. In this model, whereas vehicle-treated animals were terminated on day seven due to high disease burden, treatment with BLU-285 enabled significant disease control such that animals treated with BLU-285 at 30 mg/kg were terminated on day 22. “(Page 92) Read the full article.
Blueprint Medicines Corp. is a biopharmaceutical company, which engages in developing of kinase inhibitors for genomically defined subsets of cancer patients. It has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling the development of potent highly selective compounds against clear genomic driver targets. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA. [Source: MarketWatch]